Please Scroll Down to See Forums Below
Can nolva rid prepubertel gyno??
- Thread starter tommboy
- Start date
M
Mr.X
Guest
I would run the nolva just to be safe.
Mr.X
Mr.X
Stainless_Steel
New member
What kind of gyno causes lumps behind the nipple? Can nolva get rid of this?
FlexManning
New member
There is some anecdotal evidence for anti-es curing some pre-existing gyno, but the truth is that in a lot of cases the area is so damaged from carrying around the breast tissue that plastic surgery is required.
Personally I have some pre-existing gyno, I've taken nolva in the past and not noticed a huge difference, but I'm taking a-dex now and feel that general puffiness has been reduced. I'd be taking arimidex anyway though now that it's available at a decent price. Also, I feel that arimidex is superior to nolva while on, and that nolva is superior for PCT. Personally I wouldn't use nolva when on but that's just IMO. Nolva blocks receptors and does nothing to prevent formation of estrogen. It's great for PCT- there's even some evidence it increases natural test production. However it also blocks test from receptors. A-dex prevents formation of estrogen in the first place.
If I were you I'd simply bump the a-dex up to 1mg/day and save nolva for PCT.
Personally I have some pre-existing gyno, I've taken nolva in the past and not noticed a huge difference, but I'm taking a-dex now and feel that general puffiness has been reduced. I'd be taking arimidex anyway though now that it's available at a decent price. Also, I feel that arimidex is superior to nolva while on, and that nolva is superior for PCT. Personally I wouldn't use nolva when on but that's just IMO. Nolva blocks receptors and does nothing to prevent formation of estrogen. It's great for PCT- there's even some evidence it increases natural test production. However it also blocks test from receptors. A-dex prevents formation of estrogen in the first place.
If I were you I'd simply bump the a-dex up to 1mg/day and save nolva for PCT.
There is much more than "anecdotal evidence".
Management of physiological gynaecomastia with tamoxifen.
Khan HN, Rampaul R, Blamey RW.
Professorial Unit of Surgery, Department of Surgery, Nottingham City Hospital, Nottingham NG5 1PB, UK. [email protected]
AIMS: We aimed to confirm suggestions that tamoxifen therapy alone may resolve physiological gynaecomastia. METHODS: A prospective audit of the outcome of tamoxifen routinely given to men with physiological gynaecomastia was carried out at Nottingham. Men referred with gynaecomastia had clinical signs recorded, e.g., type (diffuse 'fatty' or retro-areolar 'lump'), size and possible aetiology. They were offered oral tamoxifen 20mg once daily for 6-12 weeks. On follow-up patients were assessed for complete resolution (CR), partial resolution where patient is satisfied with outcome (PR) or no resolution (NR). Success was either CR or PR. RESULTS: Thirty-six men accepted tamoxifen for physiological gynaecomastia. Median age was 31 (range 18-64). Tenderness was present in 25 (71%) cases. Sixteen men (45%) had 'fatty' gynaecomastia and 20 had 'lump' gynaecomastia. Tamoxifen resolved the mass in 30 patients (83.3%; CR=22, PR=8) and tenderness in 21 cases (84%; CR=0, PR=0). Lump gynaecomastia was more responsive to tamoxifen than the fatty type (100% vs. 62.5%; P=0.0041). CONCLUSIONS: Oral tamoxifen is an effective treatment for physiological gynaecomastia, especially for the lump type.
____________________________________________________________________
Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia.
Lawrence SE, Faught KA, Vethamuthu J, Lawson ML.
Department of Pediatrics, University of Ottawa, Ontario, Canada. [email protected]
OBJECTIVES: To assess the efficacy of the anti-estrogens tamoxifen and raloxifen in the medical management of persistent pubertal gynecomastia. STUDY DESIGN: Retrospective chart review of 38 consecutive patients with persistent pubertal gynecomastia who presented to a pediatric endocrinology clinic. Patients received reassurance alone or a 3- to 9-month course of an estrogen receptor modifier (tamoxifen or raloxifene). RESULTS: Mean (SD) age of treated subjects was 14.6 (1.5) years with gynecomastia duration of 28.3 (16.4) months. Mean reduction in breast nodule diameter was 2.1 cm (95% CI 1.7, 2.7, P <.0001) after treatment with tamoxifen and 2.5 cm (95% CI 1.7, 3.3, P <.0001) with raloxifene. Some improvement was seen in 86% of patients receiving tamoxifen and in 91% receiving raloxifene, but a greater proportion had a significant decrease (>50%) with raloxifene (86%) than tamoxifen (41%). No side effects were seen in any patients. CONCLUSION: Inhibition of estrogen receptor action in the breast appears to be safe and effective in reducing persistent pubertal gynecomastia, with a better response to raloxifene than to tamoxifen. Further study is required to determine that this is truly a treatment effect.
_______________________________________________________________
Int J Adolesc Med Health. 2003 Oct-Dec;15(4):359-63. Related Articles, Links
Tamoxifen treatment for pubertal gynecomastia.
Derman O, Kanbur NO, Kutluk T.
Section of Adolescent Medicine, Department of Pediatrics, Hacettepe University Faculty of Medicine, 06100 Ankara-Turkey. [email protected]
We evaluated the efficacy of the tamoxifen treatment in 37 patients with pubertal gynecomastia. All had distinct, easily palpable breast swellings with a diameter of over three cm. Pain, tenderness, and swelling associated with gynecomastia were reported by six patients. Eight of the patients were obese. One patient also suffered from varicocele. Pain and size reduction was seen in all patients with tamoxifen treatment. No long-term side effects of tamoxifen were observed. The dose of tamoxifen was increased in three patients due to poor response. Two of the treatment group had recurrence problem at follow-up. We did not need to refer any patient to surgery. Tamoxifen treatment is relatively non-toxic, may be beneficial and we think it should be considered for pubertal gynecomastia.
